AXIN2 and neoplasm: Immunostaining for β-CATENIN and in situ hybridization for AXIN2 in PDX4 showed that after ICG-001 treatment, tumor tissues displayed a reduced expression of these markers, in contrast to vehicle-treated controls (Fig. 7e).